Literature DB >> 35915180

Peripheral apoE4 enhances Alzheimer's pathology and impairs cognition by compromising cerebrovascular function.

Chia-Chen Liu1, Jing Zhao2, Yuan Fu2, Yasuteru Inoue2, Yingxue Ren3, Yuanxin Chen2, Sydney V Doss2, Francis Shue2, Suren Jeevaratnam2, Ligia Bastea4, Na Wang2, Yuka A Martens2, Wenhui Qiao2, Minghui Wang4, Na Zhao2, Lin Jia2, Yu Yamazaki2, Akari Yamazaki2, Cassandra L Rosenberg2, Zhen Wang5, Dehui Kong6, Zonghua Li2, Lindsey A Kuchenbecker2, Zachary A Trottier2, Lindsey Felton2, Justin Rogers2, Zachary S Quicksall2, Cynthia Linares2, Joshua Knight2, Yixing Chen2, Aishe Kurti2, Takahisa Kanekiyo2, John D Fryer2, Yan W Asmann3, Peter Storz4, Xusheng Wang6, Junmin Peng5, Bin Zhang7, Betty Y S Kim8, Guojun Bu9.   

Abstract

The ε4 allele of the apolipoprotein E (APOE) gene, a genetic risk factor for Alzheimer's disease, is abundantly expressed in both the brain and periphery. Here, we present evidence that peripheral apoE isoforms, separated from those in the brain by the blood-brain barrier, differentially impact Alzheimer's disease pathogenesis and cognition. To evaluate the function of peripheral apoE, we developed conditional mouse models expressing human APOE3 or APOE4 in the liver with no detectable apoE in the brain. Liver-expressed apoE4 compromised synaptic plasticity and cognition by impairing cerebrovascular functions. Plasma proteome profiling revealed apoE isoform-dependent functional pathways highlighting cell adhesion, lipoprotein metabolism and complement activation. ApoE3 plasma from young mice improved cognition and reduced vessel-associated gliosis when transfused into aged mice, whereas apoE4 compromised the beneficial effects of young plasma. A human induced pluripotent stem cell-derived endothelial cell model recapitulated the plasma apoE isoform-specific effect on endothelial integrity, further supporting a vascular-related mechanism. Upon breeding with amyloid model mice, liver-expressed apoE4 exacerbated brain amyloid pathology, whereas apoE3 reduced it. Our findings demonstrate pathogenic effects of peripheral apoE4, providing a strong rationale for targeting peripheral apoE to treat Alzheimer's disease.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35915180     DOI: 10.1038/s41593-022-01127-0

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   28.771


  83 in total

Review 1.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

2.  Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.

Authors:  Joseph M Castellano; Jungsu Kim; Floy R Stewart; Hong Jiang; Ronald B DeMattos; Bruce W Patterson; Anne M Fagan; John C Morris; Kwasi G Mawuenyega; Carlos Cruchaga; Alison M Goate; Kelly R Bales; Steven M Paul; Randall J Bateman; David M Holtzman
Journal:  Sci Transl Med       Date:  2011-06-29       Impact factor: 17.956

Review 3.  Alzheimer disease as a vascular disorder: nosological evidence.

Authors:  J C de la Torre
Journal:  Stroke       Date:  2002-04       Impact factor: 7.914

Review 4.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors:  Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

5.  Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease.

Authors:  Eric M Reiman; Kewei Chen; Xiaofen Liu; Daniel Bandy; Meixiang Yu; Wendy Lee; Napatkamon Ayutyanont; Jennifer Keppler; Stephanie A Reeder; Jessica B S Langbaum; Gene E Alexander; William E Klunk; Chester A Mathis; Julie C Price; Howard J Aizenstein; Steven T DeKosky; Richard J Caselli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-03       Impact factor: 11.205

6.  Apolipoprotein E and cognitive change in an elderly population.

Authors:  B T Hyman; T Gomez-Isla; M Briggs; H Chung; S Nichols; F Kohout; R Wallace
Journal:  Ann Neurol       Date:  1996-07       Impact factor: 10.422

7.  Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus.

Authors:  Rachel A Whitmer; Andrew J Karter; Kristine Yaffe; Charles P Quesenberry; Joseph V Selby
Journal:  JAMA       Date:  2009-04-15       Impact factor: 56.272

8.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

Review 9.  Is Vasomotion in Cerebral Arteries Impaired in Alzheimer's Disease?

Authors:  Luigi Yuri Di Marco; Eszter Farkas; Chris Martin; Annalena Venneri; Alejandro F Frangi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 10.  Basal lamina changes in neurodegenerative disorders.

Authors:  Benjamin Nguyen; Gregory Bix; Yao Yao
Journal:  Mol Neurodegener       Date:  2021-12-07       Impact factor: 14.195

View more
  1 in total

1.  Liver-ing in your head rent free: peripheral ApoE4 drives CNS pathology.

Authors:  Lesley R Golden; Lance A Johnson
Journal:  Mol Neurodegener       Date:  2022-10-04       Impact factor: 18.879

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.